But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

Alzheimer's disease is usually associated with old age. But around 5%-10% of all Alzheimer's cases occur in people under the age of 65. Early-onset ...

A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

“The benefits of Kisunla were not large enough to outweigh the risks of potentially fatal events,” the agency said, citing ...

The European Medicines Agency has rejected Lilly’s Alzheimer’s drug Kisunla for a license, saying its benefits don’t outweigh the risk of brain swelling or bleeding. The treatment for early ...

The brain's cholesterol regulation and metabolism mechanisms may make some neurons more vulnerable to damage in the early ...

Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...

Acumen Pharmaceuticals Inc (ABOS) reports robust cash reserves and advances in Alzheimer's research, despite increased R&D expenses and competitive challenges.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

As we wait for a breakthrough that can block or reverse Alzheimer’s disease, there is some consolation that we finally have three kinds of medications and a treatment that can ...